Eylea eyed as treatment for glaucoma caused by abnormal blood vessels

NCT ID NCT04519619

Recruiting now Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study is tracking 480 people with neovascular glaucoma, a serious eye condition, who are receiving the drug Eylea (aflibercept) as part of their normal care. Researchers are monitoring side effects and how well the drug controls eye pressure and vision over 6 months. The goal is to see how Eylea performs in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aflibercept (Eylea) – a drug injected into the eye to reduce abnormal blood vessel growth and pressure.
What this could lead to: If successful, this study could confirm that Eylea is a safe and effective option for managing neovascular glaucoma in routine care.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only follows patients for 6 months, so long-term effects are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neovascular glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR GLAUCOMA

Contacts and locations

Locations

Many locations
RECRUITING

Multiple Locations, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.